152 related articles for article (PubMed ID: 37330718)
1. Current and Emerging Imaging Techniques for Neurofibromatosis Type 1-Associated Cutaneous Neurofibromas.
Li Y; Blakeley JO; Ly I; Berman Y; Lau J; Wolkenstein P; Bergqvist C; Jia W; Milner TE; Katta N; Durkin AJ; Kennedy GT; Rowland R; Romo CG; Fleming J; Kelly KM
J Invest Dermatol; 2023 Aug; 143(8):1397-1405. PubMed ID: 37330718
[TBL] [Abstract][Full Text] [Related]
2. Robust surgical approach for cutaneous neurofibroma in neurofibromatosis type 1.
Chamseddin BH; Hernandez L; Solorzano D; Vega J; Le LQ
JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31038470
[TBL] [Abstract][Full Text] [Related]
3. The effect of pregnancy on growth-dynamics of neurofibromas in Neurofibromatosis type 1.
Well L; Jaeger A; Kehrer-Sawatzki H; Farschtschi S; Avanesov M; Sauer M; de Sousa MT; Bannas P; Derlin T; Adam G; Mautner VF; Salamon JM
PLoS One; 2020; 15(4):e0232031. PubMed ID: 32343738
[TBL] [Abstract][Full Text] [Related]
4. Validating Techniques for Measurement of Cutaneous Neurofibromas: Recommendations for Clinical Trials.
Thalheimer RD; Merker VL; Ly KI; Champlain A; Sawaya J; Askenazi NL; Herr HP; Da JLW; Jordan JT; Muzikansky A; Pearce EM; Sakamoto FH; Blakeley JO; Anderson RR; Plotkin SR;
Neurology; 2021 Aug; 97(7 Suppl 1):S32-S41. PubMed ID: 34230197
[TBL] [Abstract][Full Text] [Related]
5. Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas.
Ly I; Romo CG; Gottesman S; Kelly KM; Kornacki D; York Z; Lee SY; Rhodes SD; Staedtke V; Steensma MR; Blakeley JO; Wolkenstein P
J Invest Dermatol; 2023 Aug; 143(8):1388-1396. PubMed ID: 37294242
[TBL] [Abstract][Full Text] [Related]
6. A Clinicopathologic Study on the Role of Estrogen, Progesterone, and Their Classical and Nonclassical Receptors in Cutaneous Neurofibromas of Individuals With Neurofibromatosis 1.
Rozza-de-Menezes RE; Almeida LM; Andrade-Losso RM; de Souza Vieira G; Siqueira OHK; Brum CI; Riccardi VM; Cunha KS
Am J Clin Pathol; 2021 Apr; 155(5):738-747. PubMed ID: 33289020
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and clinicopathological characteristics of lipomatous neurofibromas in neurofibromatosis 1: An investigation of 229 cutaneous neurofibromas and a systematic review of the literature.
Rozza-de-Menezes RE; Brum CAI; Gaglionone NC; de Sousa Almeida LM; Andrade-Losso RM; Paiva BVB; Faveret PLS; da Silva AV; Siqueira OHK; Riccardi VM; Cunha KS
J Cutan Pathol; 2018 Oct; 45(10):743-753. PubMed ID: 29959804
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Immune Cell Populations of Cutaneous Neurofibromas in Neurofibromatosis 1.
Kallionpää RA; Peltonen S; Le KM; Martikkala E; Jääskeläinen M; Fazeli E; Riihilä P; Haapaniemi P; Rokka A; Salmi M; Leivo I; Peltonen J
Lab Invest; 2024 Jan; 104(1):100285. PubMed ID: 37949359
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study.
Cannon A; Chen MJ; Li P; Boyd KP; Theos A; Redden DT; Korf B
Orphanet J Rare Dis; 2018 Feb; 13(1):31. PubMed ID: 29415745
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Sonographic Classification of Neurofibromas in Children with Neurofibromatosis Type 1 - A Cluster Analysis.
García-Martínez FJ; Alfageme F; Duat-Rodríguez A; Andrés Esteban EM; Hernández-Martín A
Ultraschall Med; 2023 Apr; 44(2):e118-e125. PubMed ID: 34820795
[TBL] [Abstract][Full Text] [Related]
11. High-frequency ultrasound imaging for cutaneous neurofibroma in patients with neurofibromatosis type I.
Raffin D; Zaragoza J; Georgescou G; Mourtada Y; Maruani A; Ossant F; Patat F; Vaillant L; Machet L
Eur J Dermatol; 2017 Jun; 27(3):260-265. PubMed ID: 28524060
[TBL] [Abstract][Full Text] [Related]
12. Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.
Cannon A; Sarin KY; Petersen AK; Pichard DC; Wolters PL; Erickson G; Lessing AJ; Li P; Röhl C; Rosser T; Widemann BC; Blakeley JO; Plotkin SR
Clin Trials; 2024 Feb; 21(1):67-72. PubMed ID: 37269078
[TBL] [Abstract][Full Text] [Related]
13. Topical delivery of mitogen-activated protein kinase inhibitor binimetinib prevents the development of cutaneous neurofibromas in neurofibromatosis type 1 mutant mice.
Coulpier F; Pulh P; Oubrou L; Naudet J; Fertitta L; Gregoire JM; Bocquet A; Schmitt AM; Wolkenstein P; Radomska KJ; Topilko P
Transl Res; 2023 Nov; 261():16-27. PubMed ID: 37331503
[TBL] [Abstract][Full Text] [Related]
14. C2 neurofibromas in neurofibromatosis type 1: genetic and imaging characteristics.
Waqar M; Huson S; Evans DG; Ealing J; Karabatsou K; George KJ; Soh C
J Neurosurg Spine; 2018 Oct; 30(1):126-132. PubMed ID: 30485203
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive treatment of cutaneous neurofibromas (cNFs): Results of a randomized prospective, direct comparison of four methods.
Richey P; Funk M; Sakamoto F; Plotkin S; Ly I; Jordan J; Muzikansky A; Roberts J; Farinelli W; Levin Y; Garibyan L; Blakeley JO; Anderson RR
J Am Acad Dermatol; 2024 Apr; 90(4):767-774. PubMed ID: 38086517
[TBL] [Abstract][Full Text] [Related]
16. Existing and Developing Preclinical Models for Neurofibromatosis Type 1-Related Cutaneous Neurofibromas.
Staedtke V; Topilko P; Le LQ; Grimes K; Largaespada DA; Cagan RL; Steensma MR; Stemmer-Rachamimov A; Blakeley JO; Rhodes SD; Ly I; Romo CG; Lee SY; Serra E
J Invest Dermatol; 2023 Aug; 143(8):1378-1387. PubMed ID: 37330719
[TBL] [Abstract][Full Text] [Related]
17. Mast Cells in Human Cutaneous Neurofibromas: Density, Subtypes, and Association with Clinical Features in Neurofibromatosis 1.
Kallionpää RA; Ahramo K; Martikkala E; Fazeli E; Haapaniemi P; Rokka A; Leivo I; Harvima IT; Peltonen J; Peltonen S
Dermatology; 2022; 238(2):329-339. PubMed ID: 34237737
[TBL] [Abstract][Full Text] [Related]
18. Occult neurofibroma and increased S100 protein in the skin of patients with neurofibromatosis type 1: new insight to the etiopathomechanism of neurofibromas.
Karvonen SL; Kallioinen M; Ylä-Outinen H; Pöyhönen M; Oikarinen A; Peltonen J
Arch Dermatol; 2000 Oct; 136(10):1207-9. PubMed ID: 11030766
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous neurofibromas: Current clinical and pathologic issues.
Ortonne N; Wolkenstein P; Blakeley JO; Korf B; Plotkin SR; Riccardi VM; Miller DC; Huson S; Peltonen J; Rosenberg A; Carroll SL; Verma SK; Mautner V; Upadhyaya M; Stemmer-Rachamimov A
Neurology; 2018 Jul; 91(2 Suppl 1):S5-S13. PubMed ID: 29987130
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.
Ferner RE; Lucas JD; O'Doherty MJ; Hughes RA; Smith MA; Cronin BF; Bingham J
J Neurol Neurosurg Psychiatry; 2000 Mar; 68(3):353-7. PubMed ID: 10675220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
